Chugai Pharmaceutical achieved mid-year sales of 663.3 billion yen (up 14.7% YoY), operating profit of 319.6 billion yen (up 16.9%), and net income of 231.7 billion yen (up 19.2%). The company announced R&D expenses of 90.2 billion yen and a dividend of 66 yen, indicating future growth and shareholder returns.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4519-20260724-01.pdf","jir_short_summary":"Chugai Pharmaceutical achieved mid-year sales of 663.3 billion yen (up 14.7% YoY), operating profit of 319.6 billion yen (up 16.9%), and net income of 231.7 billion yen (up 19.2%). The company announced R&D expenses of 90.2 billion yen and a dividend of 66 yen, indicating future growth and shareholder returns.","jir_summary":"### Performance Overview\nChugai Pharmaceutical achieved mid-year 2026 results with sales of 663.3 billion yen (up 14.7% YoY), operating profit of 319.6 billion yen (up 16.9%), and net income of 231.7 billion yen (up 19.2%). Revenue from both domestic and international products was strong, with overseas sales increasing by 14.1% to 328.6 billion yen. R&D expenses reached 90.2 billion yen, supporting new drug approvals and expanded indications. The dividend was increased to 66 yen, further strengthening shareholder returns.\n\n### Outlook and Impact on Shareholders\nFor the full year of 2026, sales are projected to be 1.345 trillion yen (up 6.9% YoY), with net income of 485 billion yen (up 7.5%). The company will continue to promote R&D investments and new drug approvals for sustained growth. The dividend remains at 66 yen, emphasizing shareholder returns. For investors, the steady performance coupled with proactive R&D investments presents an attractive outlook.","jir_financial_highlights":"Sales Revenue: 66.33 billion yen (Up 14.7% YoY)\nOperating Profit: 319.6 billion yen (Up 16.9% YoY)\nMid-Year Net Income: 231.7 billion yen (Up 19.2% YoY)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Sales Revenue: 66.33 billion yen (up 14.7% YoY)\nOperating Profit: 319.6 billion yen (up 16.9% YoY)\nMid-Year Net Income: 231.7 billion yen (up 19.2% YoY)","jir_meta_title":"\u3010Chugai Pharmaceutical\u30112026 Mid-Year Financial Results\uff5cSales of 663.3 billion yen (Up 14.7% YoY)","jir_meta_description":"Chugai Pharmaceutical's 2026 mid-year financial results showed sales of 663.3 billion yen and net income of 231.7 billion yen. R&D and dividends are also strong, with promising growth ahead.","jir_og_title":"\u3010Chugai Pharmaceutical\u30112026 Mid-Year Financial Results\uff5cSales of 663.3 billion yen (Up 14.7% YoY)","jir_og_description":"An overview of Chugai Pharmaceutical's 2026 mid-year financial results and future outlook. Focus on sales growth and research investment for long-term growth.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88052","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n